Home  »  Companies   »  What Did We Learn From BridgeBio Pharma Inc. (NASD...

What Did We Learn From BridgeBio Pharma Inc. (NASDAQ: BBIO) Insider Trading?

BridgeBio Pharma Inc. (NASDAQ:BBIO) traded at $8.53 at close of the session on Tuesday, 11/22/22, made a downward move of -2.96% on its previous day’s price.

Looking at the stock we see that its previous close was $8.79 and the beta (5Y monthly) reads 0.58 with the day’s price range being $8.26 – $8.88. In terms of its 52-week price range, BBIO has a high of $43.96 and a low of $4.98. The company’s stock has lost about -16.70% over that past 30 days.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


BridgeBio Pharma Inc. has a market cap of $1.29 billion and is expected to release its quarterly earnings report on Feb 22, 2023 – Feb 27, 2023. Estimates by analysts give the company expected earnings per share (EPS) of -$0.99, with the EPS growth for the year raised at -$3.37 for 2022 and -$3.56 for next year. These figures represent 13.60% and -5.60% growth in EPS for the two years respectively.

According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $81.29 million, or 16.60% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the BBIO stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 25% Buy. Long term indicators on average place the stock in the category of 50% Sell.

Looking further, we note the current price level is -15.00% off its SMA20 and -17.89% from its 50-day simple moving average. The RSI (14) is pointing at 39.13 while the volatility over the past week is 7.17% and jumps to 8.57% over the past one month. The beta value is 0.58, while the average true range (ATR) is currently pointing at 0.85.

Coming back to BridgeBio Pharma Inc. (NASDAQ:BBIO), we note that the average 3-month trading volume was 1.61 million, while that of the preceding 10-day period stands at 1.43 million. Current shares outstanding are 147.94 million.

The insiders hold 4.30% of the company’s shares while institutions hold 98.10%. The data shows that short shares as of Oct 13, 2022, stood at 23.12 million at a short ratio of 12.99. This represents a 15.59% short interest in shares outstanding on Oct 13, 2022. Shares short fall in October from the previous month at 23.25 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -48.86% down in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *